LL-37 vs VIP
Well Studied vs Extensively Studied
compatible Both have anti-inflammatory properties.
Molecular Data
LL-37 VIP
Weight — 3,326 Da
Half-life Short (rapid proteolytic degradation) 1-2 minutes
Chain 37 amino acids 28 amino acids
Type Cationic antimicrobial peptide Neuropeptide
Key Benefits
LL-37
01 Direct wound healing acceleration
02 Broad-spectrum antimicrobial activity
03 Activity against resistant bacteria (MRSA, MDRPA)
04 Enhanced tissue regeneration
05 Immune modulation
06 Local antimicrobial protection
VIP
01 Potent vasodilation and blood pressure reduction
02 Strong anti-inflammatory effects
03 Immunomodulation (Th1-Th2 balance)
04 Neuroprotective effects
05 Bronchodilation
06 Cardioprotective (positive inotropic effects)
07 Insulin secretion enhancement (glucose-dependent)
08 Gut barrier and permeability regulation
Dosing Protocols
LL-37
0.5-1.6 mg/mL topical gel or 100-150 mcg injectable / Topical: Daily to twice weekly on wounds. Injectable: Once daily subcutaneous
Systemic immune support 100-150mcg Once daily
VIP
50-100 mcg per dose (up to 200 mcg in research protocols) / 1-2 times daily due to very short 2-minute half-life
General use 50-100 mcg 1-2x daily
Research protocols 100-200 mcg As directed
Side Effects
LL-37
Generally well-tolerated
Mild injection site reactions (injectable)
Local irritation at application site (topical)
VIP
Vasodilation (flushing, warmth)
Hypotension
Increased heart rate
Gastrointestinal effects (diarrhea possible)
Headache
Contraindications
Pre-existing hypersensitivity to peptides
Compromised immune status (relative contraindication)
Non-sterile wound environments
Severe hypotension
VIPoma or related tumors
Pregnancy or breastfeeding
Severe cardiac conditions
Research Evidence
LL-37 VIP
Status Well Studied Extensively Studied
References 4 studies 4 studies
Latest 2025 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.